Literature DB >> 7107025

[The pharmacokinetics of 1,000 mg erythromycin lactobionate i. v. in patients with respiratory tract infections (author's transl)].

W Sietzen.   

Abstract

Pharmacokinetic data were determined in 16 patients with respiratory tract infections who had received 1,000 mg erythromycin lactobionate i. v. The infusion lasted 60 or 30 minutes. The peak concentrations were 33.3 mg/l (60 min group) and 34.4 mg/l (30 min group). The elimination half-lives were 2.0 h and 1.9 h. The concentrations are considerably higher than those found following the peroral administration of erythromycin. We did not find a cumulative effect after four administrations at 12-hour intervals. The clinical efficacy was good.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107025     DOI: 10.1007/BF01640864

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  3 in total

1.  Micromethod for assaying serum levels of erythromycin.

Authors:  S C Bell; J W Hamman; W E Grundy
Journal:  Appl Microbiol       Date:  1969-01

2.  [Tissue penetration of erythromycin (author's transl)].

Authors:  G A Dette
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  Pharmakokinetics of erythromycin.

Authors:  H Knothe; G A Dette
Journal:  Scott Med J       Date:  1977-12       Impact factor: 0.729

  3 in total
  1 in total

1.  Side-effects due to the intravenous infusion of erythromycin lactobionate.

Authors:  R Putzi; J Blaser; R Lüthy; R Wehrli; W Siegenthaler
Journal:  Infection       Date:  1983 May-Jun       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.